Abiraterone
- Generic Name
- Abiraterone
- Brand Names
- Yonsa, Zytiga, Abiraterone Krka, Abiraterone Accord, Abiraterone Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C24H31NO
- CAS Number
- 154229-19-3
- Unique Ingredient Identifier
- G819A456D0
- Background
Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis. Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic castration-resis...
- Indication
Abiraterone is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in combination with methylprednisolone or prednisone.
...
- Associated Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Associated Therapies
- -
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2022-08-16
- Target Recruit Count
- 900
- Registration Number
- NCT05406999
- Locations
- 🇨🇳
Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Nanjing, Jiangsu, China
Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC
- Conditions
- Interventions
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Leiden University Medical Center
- Target Recruit Count
- 168
- Registration Number
- NCT05393791
- Locations
- 🇦🇺
Eastern Health Box Hill, Box Hill, Victoria, Australia
🇦🇺Border Medical Oncology Research Unit / The Border Cancer Hospital, Albury, New South Wales, Australia
🇦🇺Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
A Study of Pamiparib Combined With Abiraterone Acetate in Neoadjuvant Treatment of Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-05-17
- Last Posted Date
- 2023-01-05
- Lead Sponsor
- Hongqian Guo
- Target Recruit Count
- 30
- Registration Number
- NCT05376722
- Locations
- 🇨🇳
Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Nanjing, Jiangsu, China
🇨🇳The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 190
- Registration Number
- NCT05367440
- Locations
- 🇬🇧
Research Site, Plymouth, United Kingdom
Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-05-05
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT05361915
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸UCSD Moores Cancer Center, La Jolla, California, United States
A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Conditions
- Interventions
- First Posted Date
- 2022-03-25
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 3
- Registration Number
- NCT05295927
- Locations
- 🇺🇸
GU Research Network, Omaha, Nebraska, United States
🇺🇸Chesapeake Urology Research Associates, Towson, Maryland, United States
🇺🇸Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
- Conditions
- Interventions
- First Posted Date
- 2022-03-21
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 900
- Registration Number
- NCT05288166
- Locations
- 🇺🇸
AHN Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
🇲🇽Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, Nuevo León, Mexico
Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial
- Conditions
- Interventions
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 34
- Registration Number
- NCT05223582
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-01-28
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 160
- Registration Number
- NCT05212857
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2022-01-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT05188911
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.